TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02169882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.
Study: NCT03053518

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LifeStyle
Description: Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeStyle
Description: Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
Study: NCT02169882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other TB drugs
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other TB drugs
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other TB drugs
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant dexamethasone
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant dexamethasone
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant dexamethasone
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Study: NCT02601755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanCope app and website
Description: In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control group
Description: The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies.
Study: NCT01328015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin 5 mg pills
Description: ½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin 5 mg pills
Description: ½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.
Study: NCT02449369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preop acetaminophen IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preop acetaminophen IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preop acetaminophen IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preop orphenadrine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preop orphenadrine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop oral oxycodone & acetaminophen
Study: NCT01668420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermal stimulation
Description: hot and cold/warm and cool pads applying.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermal stimulation
Description: hot and cold/warm and cool pads applying.
Study: NCT02449369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop oral oxycodone & acetaminophen
Study: NCT03277937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiography in EUS-injection of coils + CYA
Description: Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
Study: NCT02449369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop hydromorphone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop hydromorphone IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop hydromorphone IV
Study: NCT03630393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Pressure 6 mmHg
Description: A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum Pressure 15 mmHg
Description: A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
Study: NCT02449369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop oral orphenadrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop oral oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop acetaminophen IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop orphenadrine IV
Study: NCT02275975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study: NCT05110170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01005
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX® 3.6 mg
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Study: NCT04708353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule (vitamin c)
Description: the patient will receive one placebo capsule (vitamin c) once one hour before the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group pregabalin 150
Description: the patient will receive one capsule of pregabalin 150 mg once one hour before the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group pregabalin 300
Description: the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
Study: NCT00776880

Intervention type: OTHER
Intervention: ASA scale
Description: ASA scale evaluation before operation

Intervention type: OTHER
Intervention: PPS scale
Description: PPS scale evaluation before operation
Study: NCT01980953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Phase III Tablet
Description: Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Phase III Tablet
Description: Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Tablet
Description: Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
Study: NCT04100278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care diabetes management
Description: After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
Study: NCT01073787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 10 ml/kg of normal saline will be administered over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 10 ml/kg of normal saline will be administered over 30 minutes
Study: NCT04018677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of TOGETHERCare app
Description: TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of TOGETHERCare app
Description: TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
Study: NCT04495075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visuomotor Therapy
Description: The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Motion
Description: The knee is passively moved through a range of motion.
Study: NCT00712140

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral chemotherapy
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parenteral chemotherapy
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab
Study: NCT04040790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens without a passive artificial iris
Description: Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens with a passive artificial iris with low contrast (<1:5)
Description: Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens with a passive artificial iris with high contrast (>1:5)
Description: Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide and phenylephrine
Description: Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
Study: NCT03550391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-avoidant (HA-WBRT) Radiotherapy
Description: 30Gy in 10 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: 18-20 or 22 Gy in single fraction
Study: NCT01076647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Will be injected subcutaneously (under the skin) once daily three times weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
Study: NCT02133209

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management for Headaches
Description: Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
Study: NCT01980953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Capsule
Description: Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Capsule
Description: Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Capsule
Description: Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
Study: NCT04493606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCI ProACTIVE Coaching (objective 1)
Description: Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intervention (objective 2)
Description: A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches.
Study: NCT03964207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® (T1)
Description: inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® (T1)
Description: inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Handihaler® (T2)
Description: Inhalation Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Handihaler® (T2)
Description: Inhalation Powder
Study: NCT05190614

Intervention type: DIAGNOSTIC_TEST
Intervention: The biotype of gingiva
Description: The biotype of gingival was determined by periodontal probe.
Study: NCT03481543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-line nebulization through NIV mask
Description: In-line nebulization will be given through NIV circuit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-NIV nebulization
Description: Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
Study: NCT01563159

Intervention type: OTHER
Intervention: Data collection
Description: Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
Study: NCT02570087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chronic total coronary occlusion percutaneous intervention
Description: Percutaneous intervention of chronic total coronary occlusion with stent implantation
Study: NCT04491552

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients monitored with TruGraf and TRAC testing
Description: This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
Study: NCT03597802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at workplace - Three times per week
Description: The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
Study: NCT00942305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort.
Study: NCT01081600

Intervention type: OTHER
Intervention: Imaging with 89Zr-trastuzumab PET
Description: Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
Study: NCT00800553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: 5mg o.m. p.o. for approx. 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg of placebo for approx. 2 weeks
Study: NCT00727779

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strength training
Description: eight weeks of progressively increasing resistance training will be done in both groups side-by-side
Study: NCT03597802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at workplace - Four times per week
Description: The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
Study: NCT00727779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: eight weeks of progressively increasing resistance training will be done in both groups side-by-side
Study: NCT04405258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation